Viewing Study NCT06567119



Ignite Creation Date: 2024-10-26 @ 3:38 PM
Last Modification Date: 2024-10-26 @ 3:38 PM
Study NCT ID: NCT06567119
Status: NOT_YET_RECRUITING
Last Update Posted: None
First Post: 2024-08-14

Brief Title: Preliminary Evaluation of the Safety and Tolerability of SPOT-mRNA01 Subcutaneously Administered in Healthy Subjects
Sponsor: None
Organization: None

Study Overview

Official Title: A Randomized Double-blind Placebo-controlled Exploratory Clinical Study to Evaluate the Safety and Tolerability of SPOT-mRNA01 Injection in Healthy Adult Subjects
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a first-in-human randomized double-blind placebo-controlled clinical study to evaluate the Safety and Tolerability of SPOT-mRNA01 injection in healthy adult volunteers
Detailed Description: SPOT-mRNA01 collagen 1 alpha 1 COL1A1 mRNA-loaded by Extracellular vesicles EVs can induce collagen protein grafts in dermal tissue thereby supplementing collagen and reducing wrinkle formation in collagen-depleted skin Therefore SPOTmRNA01 can provide a source of human collagen intradermally for cosmetic anti-aging use

This is a first-in-human randomized double-blind placebo-controlled single-dose dose ascending exploratory clinical study to evaluate the Safety and Tolerability of SPOT-mRNA01 administered by subcutaneous injection to healthy adult volunteers

Biopsies will be used to detect the expression of collagen in the skin of the injection area

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None